Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Randomized Phase III Study Comparing the Digital Telemonitoring Platform "CUREETY TECHCARE" to Usual Standard of Care in Patients With Triple Negative Metastatic Breast Cancer Initiating a First-line Systemic Treatment

NCT06505018 is registered in ClinicalTrials.gov with UNICANCER as lead sponsor.

NCT NCT06505018
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06505018 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Randomized Phase III Study Comparing the Digital Telemonitoring Platform "CUREETY TECHCARE" to Usual Standard of Care in Patients With Triple Negative Metastatic Breast Cancer Initiating a First-line Systemic Treatment
Lead sponsor
UNICANCER
Phase
Not applicable
Overall status
Terminated
Start date
July 25, 2024
Completion date
December 12, 2025
Enrollment
31 (actual)
Sites
51

Conditions

As the registry lists them; a condition with its own page is linked.

metastatic triple-negative breast carcinoma